Paragon Capital Management Inc. Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX)

Paragon Capital Management Inc. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 65,643 shares of the biopharmaceutical company's stock, valued at approximately $1,731,000. Royalty Pharma comprises about 1.3% of Paragon Capital Management Inc.'s investment portfolio, making the stock its 24th largest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ballentine Partners LLC lifted its stake in shares of Royalty Pharma by 3.3% in the first quarter. Ballentine Partners LLC now owns 12,541 shares of the biopharmaceutical company's stock valued at $381,000 after purchasing an additional 406 shares during the period. NEOS Investment Management LLC raised its position in Royalty Pharma by 5.0% during the fourth quarter. NEOS Investment Management LLC now owns 8,589 shares of the biopharmaceutical company's stock worth $241,000 after acquiring an additional 409 shares during the last quarter. Xponance Inc. raised its position in Royalty Pharma by 1.9% during the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company's stock worth $836,000 after acquiring an additional 606 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Royalty Pharma by 32.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 655 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in Royalty Pharma by 10.8% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company's stock worth $276,000 after acquiring an additional 887 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group lifted their target price on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, July 11th. Finally, StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of "Moderate Buy" and an average price target of $42.00.

Royalty Pharma Trading Down 1.8 %

Shares of NASDAQ:RPRX traded down $0.51 during trading on Thursday, reaching $27.73. The stock had a trading volume of 789,812 shares, compared to its average volume of 2,644,219. The business has a fifty day moving average price of $27.99 and a 200-day moving average price of $27.88. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The stock has a market cap of $16.46 billion, a P/E ratio of 21.07, a PEG ratio of 4.16 and a beta of 0.46. Royalty Pharma plc has a fifty-two week low of $25.20 and a fifty-two week high of $31.66.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. During the same period in the previous year, the firm earned $0.85 earnings per share. As a group, analysts anticipate that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 13th. Investors of record on Friday, August 16th were issued a $0.21 dividend. The ex-dividend date was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. Royalty Pharma's payout ratio is 62.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.